Technology area: Biotechnology & Pharmaceuticals
17 pending office actions • 14 art units • 16 examiners • 0 of 17 (0%) have an AI response strategy ready • 23 patents granted in the last 365 days
Ucb Biopharma S.r.l. has 18 pending office actions in Biotechnology & Pharmaceuticals. The matters span 17 examiners and 15 art units, reflecting extensive dispersion across both examiner assignments and technical examination groups. This structure requires disciplined portfolio oversight, especially for maintaining consistent claim language, disclosure positions, and response timing across separately handled matters.
ALFANO, ALAN is the busiest examiner, with 2 pending matters. That examiner has a limited concentration within the broader docket, while the remaining matters are distributed among other examiners. Counsel should therefore combine centralized strategy with file-specific analysis.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (18%) |
| §103 only | 5 (29%) |
| §112 only | 1 (6%) |
| Double-patenting + other | 2 (12%) |
| Multi-statute (no §101) | 5 (29%) |
| No statute on record | 1 (6%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALFANO, ALAN | 2 | — | — |
| HOLLAND, PAUL J | 1 | 57.3% | +64.7% |
| ORWIG, KEVIN S | 1 | 25.5% | +40.1% |
| VIGIL, TORIANA NICHOLE | 1 | 52.9% | +26.8% |
| DONOHUE, SEAN R | 1 | 41.4% | +21.0% |
| HAMA, JOANNE | 1 | 25.4% | +40.2% |
| DUTT, ADITI | 1 | 46.8% | +48.5% |
| KIM, YUNSOO | 1 | 66.0% | +34.0% |
| SCHMIDT, IZABELA MARIA | 1 | 65.7% | +42.7% |
| SCOTLAND, REBECCA LYNN | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18039498 | FORMULATIONS | SCOTLAND, REBECCA LYNN | 5d |
| 18248651 | BINDING MOLECULES THAT MULTIMERISE CD45 | OUSPENSKI, ILIA I | 33d |
| 18760979 | HUMANISED ANTIBODIES | ORWIG, KEVIN S | — |
| 18684711 | ANTI-HLA-G ANTIBODIES | HAMA, JOANNE | — |
| 18422323 | ANTIBODY MOLECULES WHICH BIND IL-17A AND IL-17F | DUTT, ADITI | — |
| 18394323 | PHARMACEUTICAL COMPOSITIONS | KIM, YUNSOO | — |
| 18277594 | ANTIBODIES | ALFANO, ALAN | — |
| 18251006 | USE OF ANTI-TREM1 NEUTRALIZING ANTIBODIES FOR THE TREATMENT OF MOTOR NEURON NEURODEGENERATIVE DISORDERS | HUYNH, PHUONG N | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18632964 | Imaging Agents | DONOHUE, SEAN R | 81d overdue |
| 18703675 | FORMULATIONS | VIGIL, TORIANA NICHOLE | 7d |
| 18813117 | CELL CULTURE METHODS | HOLLAND, PAUL J | — |
| 18760979 | HUMANISED ANTIBODIES | ORWIG, KEVIN S | — |
| 18684711 | ANTI-HLA-G ANTIBODIES | HAMA, JOANNE | — |
| 18422323 | ANTIBODY MOLECULES WHICH BIND IL-17A AND IL-17F | DUTT, ADITI | — |
| 18394323 | PHARMACEUTICAL COMPOSITIONS | KIM, YUNSOO | — |
| 18265156 | Octahydroisoquinolinyl Derivatives | SCHMIDT, IZABELA MARIA | — |
| Art Unit | Apps |
|---|---|
| 1641 | 3 |
| 1656 | 1 |
| 3991 | 1 |
| 1612 | 1 |
| 1618 | 1 |
| 1647 | 1 |
| 1675 | 1 |
| 1621 | 1 |
| 1615 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18813117 | CELL CULTURE METHODS | HOLLAND, PAUL J | 1656 | §102§103DP | Non-Final OA | — | Pending | Aug 23, 2024 |
| 18760979 | HUMANISED ANTIBODIES | ORWIG, KEVIN S | 3991 | Other | Non-Final OA | — | Pending | Jul 01, 2024 |
| 18703675 | FORMULATIONS | VIGIL, TORIANA NICHOLE | 1612 | §103 | Final Rejection | 7d | Pending | Apr 22, 2024 |
| 18632964 | Imaging Agents | DONOHUE, SEAN R | 1618 | §103 | Final Rejection | 81d overdue | Pending | Apr 11, 2024 |
| 18684711 | ANTI-HLA-G ANTIBODIES | HAMA, JOANNE | 1647 | §101§112 | Non-Final OA | — | Pending | Feb 19, 2024 |
| 18422323 | ANTIBODY MOLECULES WHICH BIND IL-17A AND IL-17F | DUTT, ADITI | 1675 | §101DP | Non-Final OA | — | Pending | Jan 25, 2024 |
| 18394323 | PHARMACEUTICAL COMPOSITIONS | KIM, YUNSOO | — | §103§112 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18277594 | ANTIBODIES | ALFANO, ALAN | 1641 | §102§112 | Non-Final OA | — | Pending | Aug 17, 2023 |
| 18265156 | Octahydroisoquinolinyl Derivatives | SCHMIDT, IZABELA MARIA | 1621 | §103DP | Non-Final OA | — | Pending | Jun 02, 2023 |
| 18039498 | FORMULATIONS | SCOTLAND, REBECCA LYNN | 1615 | §103 | Non-Final OA | 5d | Pending | May 31, 2023 |
| 18251006 | USE OF ANTI-TREM1 NEUTRALIZING ANTIBODIES FOR THE TREATMENT OF MOTOR NEURON NEURODEGENERATIVE DISORDERS | HUYNH, PHUONG N | 1641 | §102§103§112Other | Final Rejection | — | Pending | Apr 28, 2023 |
| 18248651 | BINDING MOLECULES THAT MULTIMERISE CD45 | OUSPENSKI, ILIA I | 1644 | §102§103§112 | Non-Final OA | 33d | Pending | Apr 11, 2023 |
| 18028736 | Nucleic Acid Constructs, Viral Vectors and Viral Particles | MCLEOD, AFRICA MHAIRIE | 1635 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 27, 2023 |
| 18045623 | Methods of Treatment Using Anti-IL-17A/F Antibodies | SCHWECHTER, BRANDON ROSS | 1674 | §102§103§112 | Non-Final OA | — | Pending | Oct 11, 2022 |
| 17907116 | AUTONOMOUS KNOB DOMAIN PEPTIDES | ALFANO, ALAN | 1641 | §112 | Final Rejection | 4d overdue | Pending | Sep 23, 2022 |
| 17787094 | MULTI-SPECIFIC ANTIBODIES | CHATTIN, AMY MARIE | 1643 | §103 | Non-Final OA | — | Pending | Jun 17, 2022 |
| 17286247 | METHOD FOR THE TREATMENT OF MYASTHENIA GRAVIS | HOLTZMAN, KATHERINE ANN | 1646 | §103Other | Final Rejection | 80d overdue | Pending | Apr 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUcb Biopharma S.r.l. has 17 pending office actions as of October 2026, spread across 14 art units and 16 examiners.
Alan Alfano has the most, with 2 of Ucb Biopharma S.r.l.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
